Given its central role in transcription, targeting TBP for cancer therapy presents both opportunities and challenges. Inhibiting TBP function could potentially disrupt the transcriptional machinery of cancer cells, leading to their death. However, such an approach must be carefully balanced to avoid affecting normal cells, as TBP is also critical for their function.
